Results 61 to 70 of about 53,090 (292)

Single-Domain Antibody-Based TCR-Like CAR-T: A Potential Cancer Therapy

Journal of Immunology Research, 2020
Retargeting the antigen-binding specificity of T cells to intracellular antigens that are degraded and presented on the tumor surface by engineering chimeric antigen receptor (CAR), also named TCR-like antibody CAR-T, remains limited.
Lichen Zhu, Xiaomei Yang, Dani Zhong, Shenxia Xie, Wei Shi, Yangzi Li, Xiaoqiong Hou, HuaYao, Huihui Zhou, Minlong Zhao, Ziqiang Ding, Xinyue Zhao, Fengzhen Mo, Shihua Yin, Aiqun Liu, Xiaoling Lu   +15 more
doaj   +1 more source

The CD19/CD21 Complex Functions to Prolong B Cell Antigen Receptor Signaling from Lipid Rafts

, 2001
The CD19/CD21 complex functions to significantly enhance B cell antigen receptor (BCR) signaling in response to complement-tagged antigens. Recent studies showed that following antigen binding the BCR translocates into plasma membrane lipid rafts that ...
Paul C. Cheng, Cherukuri, Anu, Cheng, Paul C., Susan K. Pierce, Pierce, Susan K., Sohn, Hae Won, Anu Cherukuri, Hae Won Sohn   +7 more
core   +1 more source

Pharmacologic Modulation of ARID3A with Rimegepant Reactivates Type I Interferon Signaling and Sensitizes Triple‐Negative Breast Cancer to PD‐1 Blockade

Advanced Science, EarlyView.
This study identifies ARID3A as a key immunosuppressive transcription factor in TNBC. Its inhibition activates the type I IFN pathway, boosting CD8+ T cell infiltration and sensitizing tumors to anti‐PD‐1. The FDA‐approved migraine drug Rimegepant targets ARID3A, enhances immunotherapy efficacy in preclinical models, and establishes a druggable axis to
Teng Zhou, Yifei Zhu, Cheng Zeng, Jinlu Han, Huiying Huang, Doudou Li, Mingxi Lin, Yizi Jin, Qin Guo, Yuxin Yan, Xinhui Mao, Yifei Zhou, Jian Zhang   +12 more
wiley   +1 more source

Association Between Serum Ferritin and CD19/CD34 Expression in Pediatric Acute Lymphoblastic Leukemia [PDF]

Journal of Bioscience and Applied Research
Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy, characterized by malignant proliferation and accumulation of lymphoblasts in the bone marrow.
Karrar Tikki, Haider Jaffat
doaj   +1 more source

Post-CD19 Chimeric Antigen Receptor T-Cell Therapy Cytomegalovirus Retinitis

Cureus, 2022
The purpose of this case report was to present a case of cytomegalovirus (CMV) retinitis in a patient with diffuse large B-cell lymphoma (DLBCL) post-CD19 chimeric antigen receptor (CAR) T-cell therapy. A 43-year-old female patient who was complaining of metamorphopsia and sudden blurring in the vision of her left eye was referred to the ophthalmology ...
Bin dokhi, Haifa, Alharbi, Amjad O, Ibnouf, Nida H, Alahmari, Bader, Refka, Mohammed N   +4 more
openaire   +2 more sources

Optimization of B Cell Responses in Human Immune System Mice Through Organoid Based Screening

Advanced Science, EarlyView.
Human immune system (HIS) mice show limited B cell responses to immunization. Using HIS mouse spleen organoids, this study identifies cytokine combinations and innate immune signals that drive human B cell expansion, differentiation, and class‐switch. Applying these signals in vivo through temporal separation enables antigen‐specific IgG responses and ...
Haiqiao Sun, He Li, Xu Zhu, Zijian Zhang, Deshan Ren, Shuai Ding, Yan Li   +6 more
wiley   +1 more source

Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data

Pharmaceutics, 2020
Chimeric antigen receptor (CAR)-T-cell therapy is an innovative form of adoptive cell therapy that has revolutionized the treatment of certain hematological malignancies, including B-cell non-Hodgkin lymphoma (NHL) and B-cell acute lymphoblastic leukemia
Gils Roex, Tom Feys, Yves Beguin, Tessa Kerre, Xavier Poiré, Philippe Lewalle, Peter Vandenberghe, Dominique Bron, Sébastien Anguille   +8 more
doaj   +1 more source

T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells [PDF]

, 2016
The adoptive transfer of T cells expressing anti-CD19 chimeric antigen receptors (CARs) has shown remarkable curative potential against advanced B-cell malignancies, but multiple trials have also reported patient relapses due to the emergence of CD19 ...
Michael C. Jensen, Yvonne Y. Chen, Anne Silva-Benedict, Jensen, Michael C, Meng-Yin Lin, Zah, Eugenia, Eugenia Zah, Lin, Meng-Yin, Silva-Benedict, Anne, Chen, Yvonne Y   +9 more
core   +1 more source

A Biomimetic Nanoparticle System Intercepts and Degrades Thrombospondin‐1 to Restore Vascular Homeostasis After Ischemic Injury

Advanced Science, EarlyView.
TAX2‐NPs capture extracellular TSP‐1 in the injured liver and promote its macrophage‐mediated autophagic degradation. This process blocks TSP‐1/CD47 signaling, restores VEGFR2‐AKT activity, preserves endothelial function, and mitigates hepatic ischemia‐reperfusion injury.
Haorui Wang, Xiandi Meng, Yanbao Xin, Kuirong Mao, Huizhu Tan, Changkai Ma, Xiuxiu Cong, Mengfei Zhao, Meiling Yu, Si Chen, Yue Hou, Yong‐Guang Yang, Tianmeng Sun   +12 more
wiley   +1 more source

Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma

New England Journal of Medicine, 2015
A patient with refractory multiple myeloma received an infusion of CTL019 cells, a cellular therapy consisting of autologous T cells transduced with an anti-CD19 chimeric antigen receptor, after myeloablative chemotherapy (melphalan, 140 mg per square meter of body-surface area) and autologous stem-cell transplantation.
Alfred L, Garfall, Marcela V, Maus, Wei-Ting, Hwang, Simon F, Lacey, Yolanda D, Mahnke, J Joseph, Melenhorst, Zhaohui, Zheng, Dan T, Vogl, Adam D, Cohen, Brendan M, Weiss, Karen, Dengel, Naseem D S, Kerr, Adam, Bagg, Bruce L, Levine, Carl H, June, Edward A, Stadtmauer   +15 more
openaire   +2 more sources